Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
140
-
Total 13F shares, excl. options
-
45.7M
-
Shares change
-
-3.83M
-
Total reported value, excl. options
-
$83.2M
-
Value change
-
-$34.9M
-
Put/Call ratio
-
0.86
-
Number of buys
-
68
-
Number of sells
-
-62
-
Price
-
$1.82
Significant Holders of ImmunityBio, Inc. - COM (IBRX) as of Q1 2023
176 filings reported holding IBRX - ImmunityBio, Inc. - COM as of Q1 2023.
ImmunityBio, Inc. - COM (IBRX) has 140 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.7M shares
.
Largest 10 shareholders include VANGUARD GROUP INC (8.29M shares), BlackRock Inc. (6.97M shares), ARMISTICE CAPITAL, LLC (5.8M shares), STATE STREET CORP (2.65M shares), PICTET ASSET MANAGEMENT SA (2.42M shares), GEODE CAPITAL MANAGEMENT, LLC (1.95M shares), JPMORGAN CHASE & CO (1.61M shares), SHEETS SMITH WEALTH MANAGEMENT (1.59M shares), TANG CAPITAL MANAGEMENT LLC (1.1M shares), and CREDIT SUISSE AG/ (890K shares).
This table shows the top 140 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.